Novo Holdings

Sparrow Quantum specializes in developing deterministic single-photon sources for advancing light-matter interfaces in quantum technologies. With a focus on high efficiency, purity, indistinguishability, and outcoupling, the company's technology is based on over two decades of research at the Niels Bohr Institute.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Founded in 2021, Commit Biologics is a Danish biotechnology company dedicated to developing innovative immunotherapy platforms for cancer treatment. Its proprietary platform employs b-specific domain antibodies to engage the body's innate immune response, targeting and destroying cancer cells.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

Stingray Marine Solutions AS is a Norwegian technology firm based in Oslo, specializing in innovative solutions for the aquaculture industry, specifically in the removal of sea lice from fish. Founded in 2010, the company has developed an advanced optical delousing system that employs camera vision and laser technology to detect and eliminate sea lice from salmon in net pens. This automated process enhances fish health management by minimizing the need for physical handling of the fish, thereby increasing productivity in salmon farming. Stingray Marine Solutions operates as a subsidiary of Beck Engineering AS and has its origins in the entrepreneurial vision of Esben Beck, who has been involved in technology development since 1999.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Founded in 2021, Commit Biologics is a Danish biotechnology company dedicated to developing innovative immunotherapy platforms for cancer treatment. Its proprietary platform employs b-specific domain antibodies to engage the body's innate immune response, targeting and destroying cancer cells.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Chromologics is a Danish biotechnology company that originated as a spin-out from the Technical University of Denmark. It develops natural food colorants derived from a fungal biotechnology platform and fermentation processes. The company's pigments are designed as a new generation of bio-based colorants with stability across a range of pH levels and temperatures, enabling their use in various food products and allowing businesses to replace carmine in current applications.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Biosyntia is a Danish biotechnology company that develops biocatalysts for fermentation-based production of fine chemicals, including natural active ingredients, vitamins, and other bioactives. It employs proprietary high-throughput screening and metabolic engineering to enable rapid creation of biocatalysts that convert feedstocks into complex compounds, with the goal of lower production costs and reduced environmental impact compared to conventional chemical synthesis. The company partners with manufacturers in flavors, fragrances, APIs, pigments, additives and related sectors to establish sustainable manufacturing processes with improved quality and traceability. Biosyntia operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm, Denmark.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Chromologics is a Danish biotechnology company that originated as a spin-out from the Technical University of Denmark. It develops natural food colorants derived from a fungal biotechnology platform and fermentation processes. The company's pigments are designed as a new generation of bio-based colorants with stability across a range of pH levels and temperatures, enabling their use in various food products and allowing businesses to replace carmine in current applications.

AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

The Renewable Energy Partnership is a partnership between Novo Holdings, Sampension, and European Energy with the intention to buy land for the construction of solar and wind farms in Denmark and Sweden. The three partners will provide DKK 650 million (approx. EUR 87 million) with the possibility of investments of up to DKK 1.5 billion (approx. EUR 200 million) through debt financing. This will significantly increase investments in the green transition in Denmark and Sweden.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

The Protein Brewery B.V. is a high-tech company based in Breda, Netherlands, focused on the development, manufacturing, and commercialization of animal-free protein products. Founded in 2019 as a spin-out from BioscienZ, the company specializes in producing Fermotein, a fungi-based protein created through advanced fermentation technologies. This innovative approach not only replaces traditional animal-based proteins but also utilizes significantly less land and water, ensuring a more sustainable production process. The Protein Brewery's products offer consumers protein-rich foods that contain all essential amino acids, vitamins, and minerals necessary for a healthy and balanced diet, all while maintaining taste and performance.

Rappta Therapeutics Oy is a biopharmaceutical company focused on developing innovative anti-cancer drugs that target protein phosphatase 2A (PP2A), an essential enzyme involved in regulating protein de-phosphorylation and tumor growth. Established in 2019 and headquartered in Helsinki, Finland, with an additional office in the United States, the company is in the lead-optimization stage, working to create a series of first-in-class molecules that aim to reactivate this vital tumor suppressor. With proprietary development tools, Rappta Therapeutics is enhancing its capacity for rational drug design, thus providing therapeutic options for a variety of cancer types and certain important non-oncology conditions.

Founded in 2016 and headquartered in Utrecht, the Netherlands, Lava Therapeutics is a biotechnology company specializing in the development of proprietary Vγ9Vδ2 T-cell engagers for immune oncology. Its platform focuses on creating bispecific antibodies to engage gamma-delta T cells for treating hematological and solid cancers.

Chromologics is a Danish biotechnology company that originated as a spin-out from the Technical University of Denmark. It develops natural food colorants derived from a fungal biotechnology platform and fermentation processes. The company's pigments are designed as a new generation of bio-based colorants with stability across a range of pH levels and temperatures, enabling their use in various food products and allowing businesses to replace carmine in current applications.

Reapplix is a Danish medical technology company that develops autologous wound therapy and tissue regeneration solutions derived from the patient's blood. It identifies and isolates blood-derived proteins to accelerate healing of chronic wounds and markets a device capable of delivering autologous active cell therapy to treat diabetic foot ulcers, with the aim of improving healing outcomes and reducing treatment costs. Founded in 2008 and based in Birkerod, Denmark, the company focuses on enabling hospitals to provide biological wound treatment using the patient's own cells.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Reapplix is a Danish medical technology company that develops autologous wound therapy and tissue regeneration solutions derived from the patient's blood. It identifies and isolates blood-derived proteins to accelerate healing of chronic wounds and markets a device capable of delivering autologous active cell therapy to treat diabetic foot ulcers, with the aim of improving healing outcomes and reducing treatment costs. Founded in 2008 and based in Birkerod, Denmark, the company focuses on enabling hospitals to provide biological wound treatment using the patient's own cells.

Founded in 2018, Stipe Therapeutics is a Danish biopharmaceutical company dedicated to harnessing the innate immune system for cancer treatment. It focuses on developing first-in-class drugs targeting intracellular protein-protein interactions of the STING pathway, aiming to modulate the tumor microenvironment and enhance anti-tumoral responses.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Founded in 2013, Forendo Pharma is a Finnish biopharmaceutical company specializing in drug discovery and development. It focuses on tissue-specific regulation of sex hormone effects to treat urological and gynecological conditions. Key products include Fispemifene for low testosterone symptoms in men and a 17HSD1-inhibitor for endometriosis.

AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, focused on developing and manufacturing treatments for mucosal diseases. Established in 2014, the company is known for its flagship product, the Rivelin® patch, which is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver medication directly to the affected area. By offering targeted therapies for conditions that currently lack approved treatment options, AFYX Therapeutics aims to enhance patient relief and support recovery without disrupting daily activities.

Precirix is a biotechnology company based in Brussels, Belgium, focused on the development of radio-immunotherapeutic drugs aimed at treating cancer patients. Established in 2014, the company utilizes the unique properties of the camelid immune system to create targeted therapies. Its innovative approach involves using antigen-binding fragments to deliver therapeutic radioisotopes directly to specific receptors on cancer cells. This method allows for a more personalized treatment option, enhancing the effectiveness of cancer therapies while minimizing damage to healthy tissue. Precirix is dedicated to advancing the field of oncology through its specialized drug development, contributing to improved outcomes for patients with various types of cancer.

Envirotainer AB specializes in the production, development, and rental of active temperature-controlled containers designed for the air transportation of temperature-sensitive healthcare products. Established in 1986 and headquartered in Upplands Väsby, Sweden, the company has built a reputation as a global leader in secure cold chain solutions for the pharmaceutical industry. Envirotainer provides a range of services, including laboratory testing, qualification and validation support, data collection, and training through its Qualified Envirotainer Program. The company's extensive network includes operations centers in key locations such as Singapore, Dallas, Frankfurt, and Toronto, as well as a station in Hyderabad, India. By leveraging its innovative container solutions and global presence, Envirotainer meets the critical needs of pharmaceutical and biotech clients for reliable shipping solutions that maintain the integrity of temperature-sensitive products.

Founded in 2013, Forendo Pharma is a Finnish biopharmaceutical company specializing in drug discovery and development. It focuses on tissue-specific regulation of sex hormone effects to treat urological and gynecological conditions. Key products include Fispemifene for low testosterone symptoms in men and a 17HSD1-inhibitor for endometriosis.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

Biosyntia is a Danish biotechnology company that develops biocatalysts for fermentation-based production of fine chemicals, including natural active ingredients, vitamins, and other bioactives. It employs proprietary high-throughput screening and metabolic engineering to enable rapid creation of biocatalysts that convert feedstocks into complex compounds, with the goal of lower production costs and reduced environmental impact compared to conventional chemical synthesis. The company partners with manufacturers in flavors, fragrances, APIs, pigments, additives and related sectors to establish sustainable manufacturing processes with improved quality and traceability. Biosyntia operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm, Denmark.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

NorthSea Therapeutics B.V. is a biotechnology company based in Naarden, the Netherlands, focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Founded in 2017, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutics, including icosabutate, which targets inflammatory and liver diseases. NorthSea Therapeutics aims to address various health conditions, such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, by delivering therapies that offer diverse biological effects. The company's pipeline reflects its commitment to advancing treatment options that enhance patient care and outcomes.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

AFYX Therapeutics A/S is a pharmaceutical company based in Copenhagen, Denmark, focused on developing and manufacturing treatments for mucosal diseases. Established in 2014, the company is known for its flagship product, the Rivelin® patch, which is designed for the treatment of oral lichen planus. This innovative patch is flexible, biodegradable, and adheres to mucosal surfaces, utilizing electrospinning technology to deliver medication directly to the affected area. By offering targeted therapies for conditions that currently lack approved treatment options, AFYX Therapeutics aims to enhance patient relief and support recovery without disrupting daily activities.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Reapplix is a Danish medical technology company that develops autologous wound therapy and tissue regeneration solutions derived from the patient's blood. It identifies and isolates blood-derived proteins to accelerate healing of chronic wounds and markets a device capable of delivering autologous active cell therapy to treat diabetic foot ulcers, with the aim of improving healing outcomes and reducing treatment costs. Founded in 2008 and based in Birkerod, Denmark, the company focuses on enabling hospitals to provide biological wound treatment using the patient's own cells.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Biosyntia is a Danish biotechnology company that develops biocatalysts for fermentation-based production of fine chemicals, including natural active ingredients, vitamins, and other bioactives. It employs proprietary high-throughput screening and metabolic engineering to enable rapid creation of biocatalysts that convert feedstocks into complex compounds, with the goal of lower production costs and reduced environmental impact compared to conventional chemical synthesis. The company partners with manufacturers in flavors, fragrances, APIs, pigments, additives and related sectors to establish sustainable manufacturing processes with improved quality and traceability. Biosyntia operates from the Novo Nordisk Foundation Center for Biosustainability in Hørsholm, Denmark.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Glionova AB is a development stage biopharmaceutical company based in Stockholm, Sweden, established in 2014. The company specializes in creating therapies for challenging cancers, with a primary focus on glioblastoma, a common and aggressive brain tumor. Its lead product, GLN-1001, is an orally bioavailable small molecule designed to selectively induce cell death in glioblastoma cells while preserving normal brain tissue. Glionova aims to advance its product through strategic partnerships with global pharmaceutical companies specializing in oncology.

Founded in 2013, Forendo Pharma is a Finnish biopharmaceutical company specializing in drug discovery and development. It focuses on tissue-specific regulation of sex hormone effects to treat urological and gynecological conditions. Key products include Fispemifene for low testosterone symptoms in men and a 17HSD1-inhibitor for endometriosis.

Pulmologix AB is a clinical stage company based in Stockholm, Sweden, that specializes in developing and manufacturing innovative treatments for respiratory diseases, particularly focusing on early onset allergic asthma. Founded in 2006, the company is dedicated to advancing oral non-steroidal anti-asthmatic drugs aimed at improving patient outcomes in asthma management. Through its research and development efforts, Pulmologix seeks to explore new medical approaches that address unmet needs in respiratory care.

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on anti-infective products, developing and manufacturing fermented and semi-synthetic active pharmaceutical ingredients and finished dosage forms for global pharmaceutical clients. It offers contract manufacturing services for antibiotics, from custom synthesis of clinical trial material to large-scale production of marketed products, along with stability testing, filling and packaging of dry powder filled vials and lyophilized vials. The company is a leading supplier of vancomycin and colistimethate sodium and operates manufacturing facilities in Europe and Asia with a global customer base across more than 70 countries. Xellia adheres to current Good Manufacturing Practice and maintains regulatory approvals from relevant authorities.

Avilex Pharma is a Danish biotechnology company spun out from the University of Copenhagen. It leverages technology from the Department of Drug Design and Pharmacology to develop dimeric peptides that target PSD95 for the treatment of neuropathic pain. The company is also developing inhibitors and neuroprotectants designed to modulate intracellular scaffolding and postsynaptic density proteins to aid recovery after ischemic stroke. Based in Copenhagen, Denmark, Avilex Pharma has backing from Novo Seeds and the Wellcome Trust.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

Chr. Hansen is a global bioscience company that specializes in developing natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural sectors. Established in 1874, the company focuses on producing cultures, enzymes, probiotics, and natural colors that enhance the flavor, texture, shelf life, and nutritional value of various products, including foods, beverages, dietary supplements, and animal feed. With a strong emphasis on research and development, Chr. Hansen employs over 2,500 individuals across 30 countries and operates main production facilities in Denmark, France, the USA, and Germany. The company's innovative offerings cater to the health and wellness needs of consumers and contribute to sustainable practices in the industry.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Orphazyme develops innovative therapies for treating lysosomal storage diseases, a family of serious genetic disorders. Based in Copenhagen, Denmark, the company collaborates with leading academic institutions worldwide.

Adenium Biotech ApS is a Copenhagen-based biopharmaceutical company founded in 2011, specializing in the development and commercialization of novel antibiotics aimed at treating multi-drug resistant bacterial infections. The company focuses on addressing hospital-acquired infections, particularly complicated urinary tract infections and pneumonia caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. Its lead product, Arenicin, is a 21-amino acid antimicrobial peptide derived from the lugworm, demonstrating strong efficacy against Gram-negative pathogens while maintaining a broad therapeutic window. Adenium Biotech operates as a semi-virtual company, relying on a small team of experts supported by an international scientific advisory board to advance its clinical development programs toward regulatory approval.

Nanoference ApS develops technology that uses nano particles to deliver Sirna molecules directly to the desired part of the body. The company was founded in 2009 and is based in Aarhus, Denmark.

Archimedes Pharma Limited is a specialty pharmaceutical company based in Reading, United Kingdom, founded in 2004. The company develops and markets a range of products aimed at addressing specific medical needs, particularly in oncology and addiction treatment. Its product lineup includes Gliadel, which is used for treating high-grade gliomas; Zomorph, an oral sustained-release morphine formulation designed for cancer pain; Nozinan, an anti-emetic effective in managing nausea and vomiting in cancer patients; and Pabrinex, a vitamin formulation targeted at alcoholics undergoing acute withdrawal. Additionally, Archimedes Pharma offers Nasalfent, an intranasal fentanyl product for cancer pain relief. The company operates across the United Kingdom, France, and Germany, emphasizing its commitment to providing specialized healthcare solutions.

EpiTherapeutics is a biotechnology company focused on developing innovative cancer therapies that leverage the science of epigenetics. Founded on research conducted by Professor Kristian Helin and his team at the Biotech Research & Innovation Centre at the University of Copenhagen, the company specializes in small-molecule therapies targeting enzymes that regulate transcription in cancer cells. EpiTherapeutics has created a library of selective small molecule inhibitors, with a particular emphasis on histone demethylases, which play a critical role in gene transcription. The company's lead compounds are currently in pre-clinical development, aimed at addressing specific types of cancer.

AlloCure, Inc. is a biotechnology company focused on developing cell therapies for kidney diseases and related conditions, including organ transplants and multi-organ injuries. Founded in 2006 and based in Burlington, Massachusetts, with additional operations in Salt Lake City, Utah, and Hamburg, Germany, AlloCure is dedicated to creating off-the-shelf biological therapies to address serious health issues affecting millions globally. The company's lead product, AC607, is a biologic therapy currently in development for acute kidney injury, with potential applications for other critical illnesses. AlloCure leverages proprietary technology utilizing processed cells derived from human bone marrow, founded by esteemed scientists Dr. Christof Westenfelder and Dr. Axel Zander, who have significant expertise in developing effective treatments for kidney diseases.

Celltrix is a Swedish biotechnology/medical device company focusing on reconstructive cosmetic surgery. Research, development and production are based in Malmö. They plan to launch the first product –Credurance – in 2010. Their product represents a new type of dermal filler. An immediate filling effect is achieved and the surrounding cells are presented to a matrix suitable for cell growth. As the cells grow on and inside the matrix, they produce their own environment, natural collagen, which gradually replaces the matrix — biorestoring.

Salmedix is an oncology drug development company with a commercial focus on the treatment of hematologic malignancies, or blood cancers. Its primary product, SDX-105, is marketed by healthcare professionals in Germany for the treatment of several types of blood cancers. Salmedix conducts Phase II clinical trials for SDX-105 in the U.S. and Canada. Its other clinical-stage product candidates, SDX-101 and SDX-102, each with significant prior human clinical experience, are also in Phase II development. Founded in 2000 by David Kabakoff, Salmedix is headquartered in San Diego, California.

Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.

Nuevolution is a prominent small molecule lead discovery company established in 2001 and headquartered in Copenhagen, Denmark. The firm specializes in developing innovative treatments for human diseases, particularly in oncology and inflammatory conditions. Central to its operations is Chemetics®, a proprietary drug discovery platform that combines wet chemistry with molecular biology, allowing for the rapid synthesis and DNA-tagging of millions of diverse small molecule compounds. This advanced technology enables efficient screening to identify potent drug leads at an unprecedented scale and speed. With a library exceeding 1 billion compounds, Nuevolution collaborates with various pharmaceutical and biotechnology companies, including notable partnerships with leading industry names. Additionally, the company is involved in a joint venture focused on the discovery and development of small molecule drugs targeting epigenetic factors. Nuevolution's capabilities have led to the identification of novel ligands with potential applications in addressing significant unmet medical needs across various therapeutic areas. The company is privately owned by a group of key Scandinavian investors.